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Abstract
HIV vasculopathy is a wide range of clinical spectrum related to HIV infection. Increasing 
longevity of HIV-infected individuals secondary to antiretroviral therapy advance-
ments has resulted in increasing the number of patients with HIV-related vasculopathy.
Clinicians need to be aware of the different types of HIV vasculopathy to be able to diag-
nose and manage the pathology and improve patient care.
Keywords: HIV vasculopathy, vascular disease, carotid disease, aortic aneurysm, 
peripheral arterial disease, cerebral vasculopathy
1. Introduction
Human immunodeficiency virus (HIV) reduces the immunity of a body, making it vulnerable 
to opportunistic diseases. HIV was first reported in the USA in 1981, in young homosexual 
men. The young men were said to have severe opportunistic infections [1]. Two years later 
the virus was labeled as HIV and acquired immune deficiency syndrome (AIDS), if advanced 
[2]. A patient is diagnosed with AIDS when their immune system is significantly low, and 
their CD4 count is <200 cells/μl. The areas most affected with HIV/AIDS-infected persons are 
the Sub-Saharan regions of Africa. More than 72% of the world’s population with HIV live in 
Africa. According to the 2007 report on HIV/AIDS, the world’s total population living with 
this infection is about 33 million [3]. The burden of the worldwide epidemic of HIV infection 
continues to increase, especially in the developing world. Third World countries experience a 
vast financial burden of managing and treating HIV-infected and affected persons with scarce 
resources. The new advancement of potent antiretroviral therapies has, however, made it pos-
sible for more patients to live longer, allowing healthcare providers to witness new clinical 
manifestations of the chronic HIV infection.
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There have been major improvements in novel clinical management in a bid to manage HIV [2]. 
For instance in 1987, HIV was for the first time linked to vasculopathy, impulsive arteriovenous 
fistula and arterial occlusive disease or aneurysmal infection [4]. The prevalence of symptom-
atic vasculitis in HIV patients is about 1% according to recent studies [5]. The chief objective of 
this review will be to describe the HIV-associated vasculopathies in various parts of the body.
Pathogenecity of HIV, which is associated with vasculopathy, is rather complex and hence 
not fully comprehended. The complexity is a result of several factors such as inflammatory 
and immunological response to HIV infections. These factors lead to deleterious and dynamic 
effects on the endothelial and smooth muscle cells of the blood vessels.
HIV infection results in several interleukins and tumor necrosis factor-α (TNF-α) in response 
to production of viral proteins by the virus. The HIV-transactivator of transcription protein 
(tat) and viral envelope glycoprotein component (gp120) are believed to induce and mediate 
the inflammatory responses to vessels. This inflammation consequently results in the produc-
tion of cytokines and adhesion molecules that interfere with endothelial function. In essence, 
the viral protein accesses the smooth muscle component of the media layer through CD4 sur-
face receptor. Ultimately, this results into abnormal proliferation of the smooth muscle, and 
abnormal activation of the coagulation cascade [6–10].
Histological studies show an infiltration of the large vessels surrounded by different inflam-
matory cells including neutrophils, lymphocytes, monocytes and plasma cells in HIV-infected 
persons. The infiltration of those cells results in obliterate endarteritis, which is an occlusion 
of the vessels supplying the vasa vasorum, and leads to ischemia, and necrotic changes of the 
vessel wall are induced [7–11]. Studies of the biopsy and culture of those aneurysms, how-
ever, fail to reveal infectious pathogens.
A murine AIDS model has helped investigate pathogenesis of acquired AIDS. In this model the 
murine leukemia virus (MuLV) is injected into mice. The mice characteristically develop hyper-
gammaglobulinemia, splenomegaly, lymphadenopathy, T-cell and B-cell functional abnormal-
ity. The mice also become highly susceptible to opportunistic infections. The murine AIDS and 
human AIDS have a lot of similarities regarding immune function alterations. Further clinical 
progression based on this model and vessel wall animal models has suggested a link between 
endothelial dysfunction and vasculopathy. It has been found that aortas from infected mice 
have increased concentrations of ICAM-1 and VCAM-1. Moreover, decrease in their contractile 
responses and impairment in the endothelium-dependent relaxation are observed.
Pathological findings, conversely, have indicated the thinning of the media layer as a result 
of the viral infection. In addition, they have indicated a direct viral invasion of the aortic 
fibroblasts at the level of the adventitia. It has therefore been postulated that an autoimmune 
destructive process can happen as a result of the similarity in the DNA sequence of the viral 
glycoprotein and a component of the matrix of the vessel wall. Important to note is that, no 
strong evidence has been found to support this theory.
It has been postulated that an autoimmune destructive process is possible where there is a 
DNA sequence of the viral glycoprotein, and a component of the matrix of the vessel wall. This, 
however, is not fully agreeable as there is lack of strong evidence to support the theory [8–12].
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To diagnose HIV-associated vasculopathy, other causes of arterial occlusions and aneurysms 
have to be eliminated. These are mycotic aneurysms caused by syphilis and tuberculosis. 
Second, arterial occlusions caused by Takayasu’s arteritis, vasculitis, and systemic lupus ery-
thematosus (SLE) and Behcet's disease. Finally, elimination of antiphospholipid antibody 
syndrome-related aneurysms which make close differentials [13–15].
Recent studies indicate that various symptoms of HIV disease have been affecting almost all 
body organs. For example, studies in radiological, clinical and postmortem indicated cerebral, 
cardiac, renal and peripheral vascular pathologies in HIV-infected persons. This chapter will 
look at different HIV-associated vasculopathies affecting the main organ systems in a body.
2. HIV-associated large vessel aneurysm
The large arteries’ condition in HIV-infected persons is not very researched, as it is a rare occur-
rence. Its pathology is different from atherosclerosis and mycotic aneurysm. It is considered a 
distinct clinical and pathological entity. It is non-infective vasculopathy, where the microbio-
logical cultures of blood, aneurysm wall and thrombus are negative. Furthermore, the patients 
with atherosclerotic aneurismal disease are older in comparison to patients with aneurysms 
related to HIV. HIV-related aneurysm is commonly found in young patients in their 30s [10–14].
While the condition stands to affect any large artery, aneurysms typically affect superficial 
femoral, carotid and popliteal artery. Aneurysms are not uncommonly found to be multiple 
and have primarily pseudoaneurysm-like focal saccular transformations. Medical practitio-
ners are therefore advised to screen patients for multiplicity using ultrasound or CT scan 
with contrast. Leukocytoclastic vasculitis of the vasa vasorum and periadventitial vessels is 
an important mechanism which weakens the wall of the vessel, and leads to focal disruption 
of the wall at the position of transmural necrosis. This mainly causes the false impression of 
aneurysm [9, 10, 13, 14]. The symptoms associated with the aneurysm depend on its location 
and size. It might be that compressive symptoms in an adjacent organ or structure result in 
life-threatening hemodynamic instability in case of a rupture. Thromboembolic and venous 
thrombosis are also likely complications of the aneurysm which have often been reported.
Majority of HIV-infected persons with associated aneurysm have advanced immunosup-
pressed state. This is usually indicated by abnormally reversed CD4:CD8 ratio. Such patients 
illustrate an abnormally low CD4 count (a median of about 400 cells/μl only). In addition, if 
such patients have high globulin level, they exhibit low serum albumin consistently [9–13].
While deciding the management approach of HIV-infected persons with asymptomatic aneu-
rysm, it’s important to take into consideration their clinical condition and nutrition status. 
With this in mind, symptomatic aneurysm lesions should be treated according to the stan-
dard guidelines, rules and open surgery standard therapy. The use of endovascular therapy 
has also gained popularity over the past years. HIV-infected patients should be optimized 
according to standard practice such as an earlier intervention. Conservative treatment on the 
other hand would be the best option for patients with advanced HIV/ AIDS. Low albumin 
(<35 g/l) and CD4 count are both indicators of poor operative outcome. Clinical management 
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should, however, maintain a consistency in administering antiretroviral therapy regardless of 
CD4 level. This is because such prevalence is indicator of an advanced phase of the condition 
[8–11, 13, 14].
3. Cerebral vasculopathy
Cerebral vasculopathy in HIV-infected patients is infrequently observed. The disease is 
believed to be under-diagnosed in most cases according to recent reports. HIV vasculopa-
thy of the central nervous system affects small- to medium-sized blood vessels. The HIV-
associated aneurysmal disease is frequently of a fusiform type, and occurs in young adults. 
This type of aneurysm affects carotids and extracranial vessels mainly. On the other hand, the 
intracranial aneurysm is a rare discovery and is often observed in children. Some reports have 
linked the low CD4 counts to increased chances of intracerebral vasculopathy occurrence [11, 
12, 15, 16].
The primary pathogenesis of intracerebral vasculopathy is not known. However, various 
studies have shown that postmortem histological examination indicates damage of the inte-
rior elastic lamina and fibrosis. This histological examination has also shown interference of 
the media along with intimal hyperplasia. The resulting aneurysmal and occlusive patterns of 
this disease tend to lead to ischemic and/or hemorrhagic complications [10–14].
The pathogenesis of HIV-associated cerebral aneurysms has also been postulated to be a 
result of immune response to the HIV protein. This occurs, according to various researches, 
inside the endothelial cell. It has been suggested that the use of antiretroviral therapy may 
exacerbate the vasculopathy because it can lead to immune reconstitution inflammatory syn-
drome (IRIS) [15, 16].
A similar theory suggested that an abnormal and significant change in the vascular response 
to blood flow, which occurs due to changes in circulating cytokines and growth factors, can 
lead to vascular remodeling. These changes are thought to play a main role in aneurismal 
dilatation. The production of cytokines and growth factors is believed to be caused by oppor-
tunistic infections, which involve the blood vessel endothelial wall, allowing it to abnormally 
increase. Such repeated infections contribute to an amplified production of elastase, which 
increases the thickness and fragmentation of the internal elastic lamina. Such changes in the 
lamina are associated with development of fusiform aneurysms. Because of this suggested 
association, patients with cerebral aneurysm should be investigated for underlying opportu-
nistic infections [11–13].
4. Carotid disease in HIV patients
Carotid intima-media thickness (IMT) measurement by B-mode high-resolution ultrasound is 
a noninvasive method of assessing atherosclerosis. It is also a strong predictor of cardiovascu-
lar events. IMT is considered in HIV persons to evaluate cardiovascular risk.
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The prevalence of carotid atherosclerosis in HIV population varies, and correlates with 
Framingham risk score (FRS). The higher the FRS, the higher the prevalence. The prevalence is 
estimated to be 26.6% in the very low-risk group and 76.5% in high-risk group. The carotid IMT 
of individuals with HIV infection was, on average, 0.04 mm thicker (95% confidence interval; and 
0.02–0.06 mm, p < 0.001) than that of individuals without HIV infection. Carotid plaque also has 
been found to be 1.5-fold more frequent in HIV patients in comparison to non-infected persons.
It is believed that the traditional CVD risk factors, in addition to HIV infection factors, play 
a role in this pathology. However, the role of ART is still not clearly confirmed. There are 
several studies that have suggested the use of ART as a significant and an independent risk 
associated with carotid atherosclerosis in HIV-infected patients. Moreover, it has been found 
that there is a moderate independent association between HIV immunological marker and 
increased carotid IMT and plaque presence [16, 17].
5. HIV-associated vascular thrombosis
Even though women comprise the highest population of HIV-infected persons in Africa, their 
male counterparts are said to be more likely to have primary arterial thrombosis. In addition, 
they are likely to present with late advanced limb ischemia. The pathophysiology of this disease 
is not well comprehended. Several causes of primary HIV infection-associated thrombosis have 
been documented. The levels of total proteins and the von Willebrand factor have been found 
to be increased in such patients. This suggested that endothelial cell dysfunction may play a 
role, as a predisposing factor for primary thrombosis. Hypercoagulable states associated with 
the HIV infection, including antiphospholipid antibody syndrome, deficiencies in free protein 
S, protein C, and antithrombin III, could predispose patients to arterial thrombosis [18, 19].
What is unique about HIV-associated vascular thrombosis is the normality of the arterial tree 
proximal to the thrombosed arteries by duplex ultrasonography, angiography and macro-
scopic appearance. Second is the thrombosis of all distal vessels with no demonstrable runoff. 
Duplex ultrasonography also showed hyperechoic ‘spotting’ in the arterial wall, the ‘string 
of pearls sign’, which has also been observed in patients with HIV-associated arterial aneu-
rysms. Both endothelial dysfunction and coagulation abnormality of the HIV patients were 
found to correlate with the state of immunosuppression [19, 20].
When managing HIV-associated occlusive vasculopathy, the vascular surgical rules should be 
followed. Patients having less CD4 count should not be excluded from surgical intervention, 
since surgical findings show that its success does not depend on CD4 levels. The treatment for 
primary arterial thrombosis includes surgical thrombectomy with or without thrombolysis. 
The use of corticosteroid post thrombectomy has been considered previously, although it did 
not decrease the rethrombosis rate. The treatment modality available unfortunately did not 
significantly alter the level of amputation. The rate of limb salvage in such cases is about 27%. 
According to therapy researches, it is clear that therapies do not address the underlying ongo-
ing processes. It’s important to note that such studies are only but a few; they are sporadic and 
reflect individual experiences [19–24].
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Venous thrombosis is reported as a complication in HIV-infected patients. It is believed to be a 
result of disturbance of coagulation process. It is estimated that deep vein thrombosis in HIV-
infected patients of up to 5% is attributable to a process of thrombophilia. In addition, protein 
anticardiolipin antibodies and protein C deficiency have been reported in such patients [25–29].
6. HIV-associated peripheral arterial disease
Peripheral arterial disease is a significant clinical management issue in HIV-infected patients. 
The disease creates a risk of cardiovascular disease, and is associated with increased morbid-
ity and mortality rate. HIV-infected individuals are believed to have higher prevalence and 
more severe forms of PAD. Measuring ankle-brachial index (ABI) is the initial noninvasive 
test to diagnose PAD. It usually correlates to obstructive disease and more than 50% stenosis 
by angiography in the lower extremity arterial system, if abnormal. Moreover, post-exercise 
ABI measurement could be used to uncover milder diseases.
Low ABI and high ABI readings have been linked to atherosclerosis and increased cardio-
vascular events. The exact prevalence of PAD in HIV population is still under-studied and 
not clearly defined. The studies are not numerous and the existing ones show contradicting 
results. However, the prevalence is believed to be higher than in normal population and in the 
range of 9.8–13.9%. High ABI prevalence in HIV patients has risen and is estimated to be in 
the range of 13.3–19.7%. However, none of the classical vascular risk factors were associated 
with ABI measurements.
Post-exercise ABI measurement change is suggestive of PAD in HIV-infected patients. It has 
been reported to range from 10.9% to 26.5%, depending on the criteria used. The exercise test 
was performed to symptomatic versus asymptomatic HIV-patients. Interestingly, the post-
exercise changes in ABI are not associated with traditional atherosclerosis risk factors such 
as diabetes mellitus, hypertensive disorder and dyslipidemia. Screening for subclinical PAD 
using post-exercise measurement is encouraged in HIV-infected patients, even when they 
do not depict symptoms of PAD. PAD has a frequent occurrence in young HIV population 
and coexists with critical limb ischemia. In HIV-infected patients, there is growing evidence 
suggesting a high prevalence of PAD and a higher risk of developing severe and accelerated 
atherosclerosis. PAD in HIV patients is six-fold more than in HIV-negative patients [30–33].
The antiretroviral protease inhibitor induces dyslipidemia, making HIV infection a risk factor 
for atherosclerosis. HIV causes direct injury to the arterial wall, resulting in the initiation of 
the inflammatory process. Such inflammations contribute to the development of premature 
atherosclerosis. Endothelial dysfunction in HIV-infected patients is associated with increas-
ing levels of soluble adhesion molecules, cytokines and procoagulant proteins. The effect of 
the HIV-associated proteins gp(120 )on endothelium have been suggested to cause endothe-
lial dysfunction [25–28, 32, 33]. In addition, PAD in HIV-infected patients can occur even in 
undetectable viral levels or in absence of severely suppressed immune system. This can be 
explained by the chronic inflammatory state in HIV patients. PAD, in addition, does not cor-
relate to Framingham risk score in the HIV-infected population [34].
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7. HIV and atherosclerotic coronary artery disease
HIV-infected patients live longer since the introduction of ART. It is believed that the risk 
of atherosclerosis in HIV patients is increased because of associated metabolic disturbances. 
The coronary disease in such infected individuals is considered distinctive. It is usually more 
diffuse and is associated with circumferential-intimal thickening, atherosclerotic plaques and 
abnormal proliferation of the smooth muscle. The muscles with luminal protrusions share 
several similarities with cardiac transplant vasculopathy [34–38]. Reports have suggested that 
the most common initial presentation of the HIV patient with CAD is acute myocardial infarc-
tion and its mortality can go as high as 24%. In addition, more than 40% test positive to triple 
vessel disease [39–41].
Coronary artery disease (CAD) is commonly observed in patients who are on ART. During a 
study conducted on this, HIV-infected patients who were not using ART showed a slight risk 
of ischemic heart disease. The risk was slightly higher in HIV-infected persons who were on 
ART. However, during the post-ART period there was a significant increase in the risk of isch-
emic cardiac disease in the HIV-infected population. The 3-year risk for myocardial infarction 
was 3.6-fold higher in patients on ART in comparison to those who were not [34, 38–43].
There are numerous metabolic changes that are associated with ART (protease inhibitor 
in particular). They include impaired glucose metabolism and lipodystrophy as a result of 
increased insulin insensitivity, and they tend to accelerate the atherosclerosis process. The 
data regarding nucleoside reverse transcriptase inhibitors, as a risk for CAD, are not very 
clear. In a D.A.D study, abacavir and didanosine were found to be associated with increased 
risk of myocardial infarction. Consequently, abacavir has been linked to higher cardiovas-
cular events in first 6 months of the infection. Conversely, other studies could not establish 
a similar relationship, especially after controlling the traditional cardiovascular risk factors. 
Furthermore, no link was established in non-nucleoside reverse transcriptase inhibitors and 
integrase inhibitors as an association with cardiovascular events [20, 44–47].
On one hand, HIV infection has been postulated to independently increase the risk of prema-
ture CAD. The mechanism by which the virus can accelerate atherosclerosis is multifactorial 
and complex. This mechanism involves the activation of inflammatory cells, which changes 
the immune response in HIV patients. This leads to exposure to a variety of xenoantigens 
from HIV infection and other viral and bacterial infections. These infections result in the igni-
tion of a continuous inflammatory condition that speeds up atherosclerosis [21, 30, 34].
Endothelial dysfunction is an early marker of atherosclerosis. Endothelial dysfunction has been 
found in young HIV-infected individuals and has been attributed to increased viral load. HIV 
affects directly the endothelium function and results in increased levels of prothrombotic plasma 
markers such as von Willebrand factor, b2 microglobulin and thrombomodulin. In addition, it 
leads to increased levels of the circulating inflammatory molecules, interleukin 6 and D-dimer.
Prevention of CAD is a cornerstone in clinically managing HIV-infected patients. Careful 
cardiac screening of individuals who are receiving ART is important. Patients with a history 
in cardiovascular risk factors stand to benefit from such screening as they are at a higher risk. 
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Identification of asymptomatic atherosclerotic diseases of the coronaries would help to maxi-
mize patients’ therapy. By the use of risk stratification tests such as coronary artery calcium 
score, high sensitivity C-reactive protein and carotid intima-medial thickness, HIV patients 
with higher risk of cardiovascular events can be identified. This will protect such patients 
from aggressive risk factors through modification and preventive measures.
Interruption of chronic ART therapy is highly discouraged as it could lead to increase in 
cardiovascular-associated morbidity and mortality. The SMART study has shown that the 
risk of cardiovascular morbidity and mortality has increased significantly. This is in patients 
who were assigned to a CD4 cell count guided therapy arm, as compared to their counter 
parts with continuous therapy arm. However, no studies or theories support an association of 
CD4 count and CAD [34, 43].
The conventional cardiovascular risk factors are found to be higher in HIV patients. Patients 
with smoking habits particularly, experience increased risk of atherosclerosis and increase the 
prothrombotic state [38, 39]. Controlling and modifying the risk factors and comorbidities is 
important in managing atherosclerosis. The fasting lipids should be checked before starting 
ART, and followed up to adjust therapy according to the lipids’ value changes. If statin therapy 
is needed to treat high low-density lipoprotein (LDL) levels, the dose to be used should be 
identified carefully. This is because the risk of statin drug interaction and possible rhabdomy-
olysis is higher in HIV patients. PI, ritonavir and some antimicrobial agents inhibit specific 
cytochrome P450 enzymes, which are important in metabolizing several statins. This is because 
such agents could increase the toxicity of those drugs. Pravastatin (20–40 mg), low-dose ator-
vastatin (10 mg) and rosuvastatin (5–10 mg) have been suggested as safe if used with prote-
ase inhibitors. Ezetimibe can also be added to statin therapy to achieve target levels of LDL. 
Fibrates are used to control hypertriglyceridemia, if the concentration is above 500 mg/dL.
8. Pulmonary arterial hypertension
HIV-related pulmonary arterial hypertension (PHT) is estimated to occur in 0.5% of the HIV 
population. It is usually present with nonspecific symptoms such as dyspnea on exertion, 
lower extremity edema and fatigue. PHT is considered a poor prognostic finding and it is said 
to lead to right ventricular dysfunction, therefore significantly increasing the mortality rate.
The pathogenesis of HIV-related PHT is complex and still not very well understood. Factors 
that are believed to participate in the pathogenesis are related to the viral infection in patients. 
It is believed that the HIV virus stimulates an immune response, which leads to the release 
of different cytokines and growth factors. This may include the potent vasoconstrictors, 
endothelin-1, interleukin 6, tumor necrosis factor and platelet-derived growth factor. These 
immunological responses result in endothelial damage, intimal fibrosis, and stimulate the 
proliferation of the smooth muscle and fibroblast of the arterioles. Eventually, the pathologi-
cal structural changes lead to the formation of plexiform lesion. The lesion is quite similar 
to those found in PaHTN caused by other factors. More recent evidence suggests that the 
patient’s immunologic response, virus HIV-negative factor (Nef), HIV-transactivator of tran-
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scription (Tat) accessory proteins and human herpes virus-8 coinfection, may play an impor-
tant role to cascade events.
Its prognosis is poor and the reported mortality rate is said to be high. PaHTN in HIV popula-
tion is an independent predictor of mortality with 1-year survival rate reported to range from 
51% to 88%. The severity of HIV infection and CD4 cell count has no apparent correlation 
with this complication. The effect of highly active antiretroviral therapy regimens on the clini-
cal course is still not well defined and is presently being investigated. However, it has been 
suggested that long-duration treatment with HAART might reduce mortality rate. Currently 
the treatment of HIV-PaHTN is similar to that of idiopathic pulmonary arterial hypertension 
patients. There have been reports of the use of diuretics, anticoagulation, phosphodiesterase 
V inhibitors and calcium channel blockers to treat HIV-PaHTN. HAART prostacyclin analogs 
(e.g.epoprostenol and endothelin) and receptor inhibitors (such as bosentan) were found to be 
effective in reducing the pulmonary arterial pressure in HIV patients. Heart-lung transplanta-
tion is the last treatment option in this subgroup of patients [21, 22, 34].
9. Conclusion
HIV-associated vascular diseases is not a common occurrence, even though it is considered 
to be of significant clinical importance. A comprehensive screening for possible etiology such 
as co-infections, lymphoproliferative disease, and autoimmune disorders, before other patho-
logical attributions to HIV infection is important for appropriate patients’ management. HIV-
associated vascular disease can be manifested either as aneurysms or occlusive forms. The 
two forms of diseases can lead to hemorrhagic or ischemic life-threatening complications, 
respectively.
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